A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays
JR Currier, EG Kuta, E Turk, LB Earhart… - Journal of …, 2002 - Elsevier
Vaccines in general and HIV vaccines in particular are focusing ever more on the induction
of cellular immunity specifically the generation of cytotoxic T cells (CTL). As progress is made …
of cellular immunity specifically the generation of cytotoxic T cells (CTL). As progress is made …
A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates
…, M Dong, I Swafford, JB Case, JR Currier… - Science translational …, 2021 - science.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
stresses the continued need for next-generation vaccines that confer broad protection …
stresses the continued need for next-generation vaccines that confer broad protection …
[PDF][PDF] SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity
…, LW Kummer, TJ Lang, SE Muncil, JR Currier… - Cell reports, 2021 - cell.com
The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation
vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term …
vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term …
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120
…, X Shen, GD Tomaras, JR Currier… - AIDS research and …, 2012 - liebertpub.com
The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1 acquisition.
Plasma collected from HIV-1-uninfected trial participants completing all injections with …
Plasma collected from HIV-1-uninfected trial participants completing all injections with …
CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus …
C Geldmacher, JR Currier, E Herrmann… - Journal of …, 2007 - Am Soc Microbiol
The importance of HLA class I-restricted CD8 T-cell responses in the control of human
immunodeficiency virus (HIV) infection is generally accepted. While several studies have shown …
immunodeficiency virus (HIV) infection is generally accepted. While several studies have shown …
[HTML][HTML] Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques
…, DH Barouch, MC Wise, BS Lewis, JR Currier… - PLoS …, 2017 - journals.plos.org
Studies have demonstrated cross-reactivity of anti-dengue virus (DENV) antibodies in human
sera against Zika virus (ZIKV), promoting increased ZIKV infection in vitro. However, the …
sera against Zika virus (ZIKV), promoting increased ZIKV infection in vitro. However, the …
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope
…, B Mathieson, M Marovich, JR Currier… - The Journal of …, 2012 - journals.aai.org
The Thai HIV phase III prime/boost vaccine trial (RV144) using ALVAC-HIV (vCP1521) and
AIDSVAX B/E was, to our knowledge, the first to demonstrate acquisition efficacy. Vaccine-…
AIDSVAX B/E was, to our knowledge, the first to demonstrate acquisition efficacy. Vaccine-…
[HTML][HTML] Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate
JR Currier, V Ngauy, MS de Souza, S Ratto-Kim… - PloS one, 2010 - journals.plos.org
Background We conducted a Phase I randomized, dose-escalation, route-comparison trial of
MVA-CMDR, a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara …
MVA-CMDR, a candidate HIV-1 vaccine based on a recombinant modified vaccinia Ankara …
[HTML][HTML] A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge
…, P Mudvari, SJ Krebs, AS Pekosz, JR Currier… - npj Vaccines, 2021 - nature.com
The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of
vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (…
vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (…
[HTML][HTML] SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses
The emergence of variants of concern, some with reduced susceptibility to COVID-19
vaccines underscores consideration for the understanding of vaccine design that optimizes …
vaccines underscores consideration for the understanding of vaccine design that optimizes …
